Evidence map›Paper›PMID 34893758›Full record

ArticleLaboratory investigation; a journal of technical methods and pathology2022

Smoothened (SMO) regulates insulin-like growth factor 1 receptor (IGF1R) levels and protein kinase B (AKT) localization and signaling.

Nitin K Agarwal, Chae-Hwa Kim, Kranthi Kunkalla, Amineh Vaghefi, Sandra Sanchez, Samantha Manuel, Daniel Bilbao, Francisco Vega, Ralf Landgraf

Open access · greenAbstract read
In one paragraph

Article in Laboratory investigation; a journal of technical methods and pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Frontiers in immunology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Nitin K AgarwalDivision of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA.
Chae-Hwa KimDivision of Hematopathology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
Kranthi KunkallaDivision of Hematopathology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
Amineh VaghefiDivision of Hematopathology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
Sandra SanchezDivision of Hematopathology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
Samantha ManuelSheila and David Fuente Graduate Program in Cancer Biology, Miller School of Medicine, University of Miami, Miami, FL, USA.
Daniel BilbaoSylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
Francisco Vega *Division of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA. fvega@mdanderson.org.ORCID http://orcid.org/0000-0001-5956-452X
Ralf Landgraf *Sheila and David Fuente Graduate Program in Cancer Biology, Miller School of Medicine, University of Miami, Miami, FL, USA. RLandgraf@med.miami.edu.
University of Miami · USThe University of Texas MD Anderson Cancer Center · US

Funding

Smoothened as a Novel Signal Stabilization Scaffold in Doxorubicin ResistanceR01CA222918 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI LANDGRAF, RALF, VEGA-VAZQUEZ, FRANCISCO · 2019 to 2023
$2.4M
NCI NIH HHS R01 CA222918
6 · The paper itself

Abstract

The oncoprotein Smoothened (SMO), a Frizzled-class-G-protein-coupled receptor, is the central transducer of hedgehog (Hh) signaling. While canonical SMO signaling is best understood in the context of cilia, evidence suggests that SMO has other functions in cancer biology that are unrelated to canonical Hh signaling. Herein, we provided evidence that elevated levels of human SMO show a strong correlation with elevated levels of insulin-like growth factor 1 receptor (IGF1R) and reduced survival in diffuse large B-cell lymphoma (DLBCL). As an integral component of raft microdomains, SMO plays a fundamental role in maintaining the levels of IGF1R in lymphoma and breast cancer cells as well IGF1R-associated activation of protein kinase B (AKT). Silencing of SMO increases lysosomal degradation and favors a localization of IGF1R to late endosomal compartments instead of early endosomal compartments from which much of the receptor would normally recycle. In addition, loss of SMO interferes with the lipid raft localization and retention of the remaining IGF1R and AKT, thereby disrupting the primary signaling context for IGF1R/AKT. This activity of SMO is independent of its canonical signaling and represents a novel and clinically relevant contribution to signaling by the highly oncogenic IGF1R/AKT signaling axis.

Indexed as

Insulin-Like Growth Factor IProto-Oncogene Proteins c-aktHedgehog ProteinsHumansReceptor, IGF Type 1Receptors, G-Protein-CoupledSignal TransductionSmoothened ReceptorHedgehog ProteinsIGF1R protein, humanInsulin-Like Growth Factor IProto-Oncogene Proteins c-aktReceptor, IGF Type 1Receptors, G-Protein-CoupledSmoothened ReceptorSMO protein, human

Identifiers

PMID34893758
PMCPMC8969180
OpenAlexW4200264803

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.